26
Aug

Novartis’ big generics operation at Sandoz has been one of the leaders in the field of biosimilar development. So when the chief lays out a timetable on the adoption of these long-awaited knockoffs of some of the industry’s biggest biologics, FierceBiotech listens.

…read more

Source: Novartis CEO predicts a looming biosimilars boom

    

0 No comments